Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
US Myeloma Immunotherapy Consortium data on impact of extramedullary plasmacytoma on outcomes in RRMM pts (N=360) txd w/ talquetamab find preserved response rates (63-68%) in EMD & PSD but shorter PFS (4.3-7.8 mos) and OS.”
Title: Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium
Authors: Aimaz Afrough, Oren Pasvolsky, Andrew J. Portuguese, Saurabh Zanwar, Mahmoud R. Gaballa, Aishwarya Sannareddy, Danai Dima, Utkarsh Goel, Hossam M. Ali, Kelley Julian, Andre De Menezes Silva Corraes, Murali Janakiram, Scott Goldsmith, James A. Davis, Kimberly Green, Noa Biran, Lindsay Fogel, Eli Zolotov, Megan M. Herr, Hamza Hassan, Leyla Shune, Jeries Kort, Christina Ye, Susan Bal, Luciano J. Costa, Laura Joiner, Samer AL Hadidi, Adeel M. Khan, Shahzad Raza, Faiz Anwer, Jack Khouri, Rahul Banerjee, Raffaela Cassano Cassano, Surbhi Sidana, Masooma Shifa Rana, Lekha Mikkilineni, Hitomi Hosoya, Shebli Atrash, Christopher Ferreri, Cindy Varga, Douglas W. Sborov, Shonali Midha, Omar Nadeem, Ariel Grajales-Cruz, Rachid Baz, Brandon Blue, Ciara Freeman, Frederick L. Locke, Krina K. Patel, Yi Lin, Shaji K. Kumar, Doris K. Hansen, Larry D. Anderson Jr., Peter M. Voorhees, Omar Castaneda-Puglianini
You can read the full article on Blood Cancer Journal.
You can find other articles featuring Robert Orlowski on OncoDaily.
